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ABSTRACT 
Flupirtine is a non-opioid analgesic without antipyretic or antiphlogistic properties. Flupirtine is a centrally acting analgesic but the analgesic 
action of flupirtine does not depend on any central opioid effect. The fact behind this statement is that the pain-relieving property of flupirtine is 
not reduced by the opioid antagonistic drug naloxone. Flupirtine has been reported for its neuro-protective properties and possess a selective 
neuronal potassium channel opener that also has NMDA receptor antagonist properties. Flupertine is transformed into two primary derivatives, 
4-fluoro-hippuric acid and the Nacetylated analogue D13223. Both derivatives of are flupirtine pharmacologically active with 30% of the 
analgesic potency of the parent drug and further oxidized and then conjugated with glycine to form inactive  metabolites, Recently, Flupirtine 
maleate  has been introduced in Indian market in oral, intravenous and rectal dosage forms. The half life of flupirtine following intravenous 
administration was 1.8 hours, while the plasma elimination half life in healthy young volunteers following single dose administration of 
flupirtine by the intravenous, oral and rectal routes was 8.5, 9.6 and 10.7 hours respectively. There is plenty of literature available on the effect of 
Flupirtine maleate on chronic and acute pain management. These preliminary finding require confirmation in further comparative studies. 
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Flupirtine maleate is an aminopyridine , clinically use as a 
nonopioid analgesic and belongs to the class of N-methyl-D-
aspartate (NMDA) antagonists1. In Europe, Flupirtine is in use 
for the last 25 years for the management of pain due to 
surgery, pain associated with muscle spasm, degenerative 
joint diseases, trauma, cancer, dental extraction and other 
conditions such as headache and dysmenorrhoea2. It has been 
proved that flupirtine is effective at least as the non-steroidal 
anti-inflammatory agents as suprofen, diclofenac and 
ketoprofen, as well as the dihydrocodeine and pentazocine 
and opiate analgesics codeine, dipyrone and paracetamol3. 
According to the AHCPR Clinical Practice Guidelines 
“Unrelieved pain has negative physical and psychological 
consequences. Aggressive pain prevention and control that 
occurs before, during, and after surgery can yield both short-
term and long-term benefits4. There are a number of 
medications available for the treatment of pain such as non-
steroidal anti-inflammatory drugs (NSAID), opioids, and their 
derivatives5. In pharmaceutical research, the investigation of 
compound for the treatment of both acute and chronic pain is 
a great challenge. Pain is a specific enteroceptive sensation; it 
can be perceived as arising from a particular portion of the 
body, its temporal properties can be detailed, it can be 
differentiated qualitatively (for example, as stinging, pricking, 
burning, throbbing, dull or aching), and it involves dedicated 
subsets of peripheral and central neurons6. Flupirtine has 
been reported for its neuro-protective properties and possess 
a selective neuronal potassium channel opener that also has 
NMDA receptor antagonist properties7. Flupirtine used as an 
analgesic for chronic pain like migraines and gynaecology. In 
addition, flupirtine has muscle relaxant properties thus it is 
used for backache and other orthopaedic purposes. It has 
neuroprotective characteristics and has possible applications 
in multiple sclerosis, Batten disease, Alzeimer’s disease and 
Creutzfeld- Jakob disease8. In 1984, it was firstly authorised in 
the European Union (EU) as the non-steroidal anti-
inflammatory drugs (NSAIDs) and an alternative analgesic to 
opioids for the pain treatment. At Present, it is authorized for 
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the treatment of acute pain in adults as an alternative when 
other analgesic treatment is contraindicated9.  Liver toxicity 
and cardiac effects in patients are some of the side effects10. 
CHEMISTRY OF FLUPIRTINE MALEATE  
Chemical structure of flupirtine is-2-amino-3-ethoxy-
carbonylamino-6-4-fluorobenzylamino- Pyridine11. It is a 
weak lipophilic, alkaline in nature with 5.3 pKa value (Fig.1). 
The carbamate group is a key feature of flupirtine and it can 
be cleaved under strong acid and basic conditions12. 
 
Fig. 1 Chemical structure of flupirtine maleate. 
PHARMOCODYNAMICS  
Flupirtine is a centrally acting analgesic but the analgesic 
action of flupirtine does not depend on any central opioid 
effect. The fact behind this statement is that the pain-relieving 
property of flupirtine is not reduced by the opioid 
antagonistic drug naloxone13,14. It was later determined that 
flupirtine interacted with G-protein regulators and secretly 
react with K+ channels (GIRKs)  which is a recognised family 
of K+ channels distinct from the voltage-dependent14. GIRKs 
are regulated by neurotransmitters, occur as different 
subtypes and are variously expressed in different parts of the 
brain15. By the activation of K+ channel hyperpolarisation 
occurs in neuronal membrane and neurons become less 
excitable and resting neuronal membrane is stabilized16. This 
channel of drug activation is known as selective neuronal 
potassium channel openers (SNEPCO) and flupirtine is the 
prototype17. Osborne and collgue, investigated that flupirtine 
might suppress channel opening by acting as an oxidizing 
agent at the redox site of the NMDA receptor which leads to 
inhibition of the transmission of nociceptive impulses during 
neuronal excitation18. A group of neuronal channels has been 
characterized and classified as Kv7.2–Kv7, as a result of good 
efficiency SENCO homology with a cardiac channel which is in 
the pathogenesis of the long QT syndrome (Kv7.1) 19,20. These 
channels provide the basis of the neuron-specific M-current, a 
voltage-dependent, non-inactivating, and slowly activating/ 
deactivating K+ current, which contributes to setting the 
resting membrane potential, limits the action potential 
frequency and participates in spike-frequency adaptation21-26. 
The efficacy of flupirtine in migraine was determined when a 
group of 20 patients suffering were treated with 100mg with 
paracetamol 1000mg, each taken up to 4 times daily for 5 
days. Similar number of doses was taken in both groups (6.65 
vs 6.85, respectively) .results shown the equal effect of both 
groups and there is no significant difference in the number of 
days of work missed, the number of patients confined to bed 
or those patients experiencing nausea27.  
PHARMACOKINETICS 
Flupertine is transformed into two primary derivatives, 4-
fluoro-hippuric acid and the Nacetylated analogue D13223 
shown in Fig. 2. The effect of flupirtine is parallel in healthy 
and renal impaired patients with 275 and 263 ml/min, 
respectively, but it is decreases about 161 ml/min in old age 
patients28,29. In a pharmacokinetic study of flupirtine in 
patients with moderate renal impairment and in healthy 
elderly subjects, oral administration of 100mg, it was found 
that elimination half-life of flupirtine was higher in elderly 
patients than in younger normal subjects, and this was 
associated with an increased maximum serum concentration 
and reduced clearance. There was no correlation between 
observed elimination half-life and degree of renal impairment, 
but the creatinine clearance of most patients fell in a narrow 
range between 43 and 60 ml/min. The mean half-life in 
patients with renal impairment was higher than in normal 
subjects. Flupirtine is mainly isolated from urine (72%)29,30. 
Flupirtine is a hydrophilic in nature. It is rapidly absorbed 
from gastrointestinal tract within 15-30 minutes with 
bioavailability of 90% by oral route and 70% by rectal route 
and reaching a peak plasma concentration of approximately 
0.8 mg/l at 1.6 to 2 hours after 100mg oral dose29-31. In a 
rectal dose of l50mg, a similar peak plasma concentration is 
reached in 5.7 hours. Binding of flupirtine to human plasma 
protein in vitro is about 80% and has an apparent volume of 
distribution for oral flupirtine 100 mg is 154 l in healthy 
volunteers30. At 200 mg flupirtine, plasma drug concentration 
(Cmax) becomes double i.e., 1.98 mg/l. Rectal administration 
also showed the dose dependent plasma drug concentration. 
Steady-state concentration is achieved at oral dose of 75mg 
flupirtine in healthy volunteers 12hrs. Both derivatives of are 
flupirtine pharmacologically active with 30% of the analgesic 
potency of the parent drug and further oxidized and then 
conjugated with glycine to form inactive metabolites31-33.  
          
Figure 2: Derivatives of flupiritine maleate 
TOLERABILITY OF FLUPIRTINE 
The tolerability profile of flupirtine is higher to facilitate the 
opioids, which may be cause dizziness and tiredness, 
constipation, vomiting, Headaches sedation, pruritus, urinary 
retention and respiratory depression34-36. Allergic reactions 
such as urticaria are also denoted. Occasionally, an increase in 
liver enzymes is induced and the urine may take on a greenish 
discoloration without any associated symptoms37. According 
to the data filed in ASTA Medica,  a clinical study done with 
8478 patients and  observed results revealed the volume of 
adverse effect of flupirtine such as, fatigue/somnolence 
(13.4%), dizziness/vertigo (7%), nausea (5.7%), headache 
(2.7%), dry mouth (2.1%), dyspepsia (1.7%), sweating (1.3%) 
and vomiting (1.3%). In the first 6 month treatment of 
flupirtine such actions have been reported as mild and 
transient36. There is no clinically significant alterations  have 
been observed in flupirtine  in laborator parameters or vital 
signs, including blood pressure, heart rate, ECG, renal 
function, haematologic and metabolic parameters. Adverse 
reactions are dose dependent and usually subside in the 
course of treatment or soon after discontinuation. There are 
no medically pertinent interactions. In comparative study of 
flupirtine with dihydrocodeine depressed mood were 
statistically more frequent, but the latter was associated with 
a significantly higher incidence of drowsiness38-40. The use of 
NSAIDs is limited by gastrointestinal adverse events, 
including dyspepsia, which has been reported to occur in up 
to 40% of NSAID recipients41. Anxiety were not observed in 
the dose of 400 to 500 mg/day orally or 600 to 750 mg/day 
rectally for 2 to 3 days42. In hepatic dysfunction, there is a 
limited data present on the adverse effect of flupirtine in 
elderly patients where as in a single-dose study of elderly 
healthy volunteers, in 5 of II subjects shown adverse 
reactions, consisting of transient faintness, dizziness or 
lethargy, but there were no clinically significant changes in 
heart rate or blood pressure29. Similarly, at 100mg dose of 
flupirtine 4 times daily for two weeks there is slight increase 
in leukocyte. This slight change is not clinically important. 
During the last month of treatment; there is increase in 
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thrombocyte count, noted in 10 of the 55 patients. There is no 
change in Blood glucose, triglyceride and cholesterol values. 
In contrast, systolic blood pressure was decreased in first 3 
month treatment from average value of 160 to 150mm Hg 
while diastolic blood pressure and heart rate was 
unchanged43. The efficiency of flupirtine maleate 100 mg 
thrice daily was compared to tramadol hydrochloriode 50 mg 
thrice daily in postoperative pain management for a period of 
5 days by taking 113 volunteer patients.  The 104 meet the 
insertion criteria and were further divided into two treatment 
groups. One group received flupirtine maleate orally and the 
other received tramadol hydrochloride orally. Significant 
reduction in pain score was found in the flupirtine group 
having equal efficacy to tramadol group but much less adverse 
effects were seen (7.4%). Hence, oral administration of both 
tramadol and flupirtine was found to be helpful in avoiding 
the adverse effects of opioids and NSAIDs 44. 
DRUG INTERACTION 
There is no evidence for short term (three weeks) oral 
administration to determined the hepatic enzyme induction 
by flupirtine at 100mg dose (3 times daily), while although  at 
double time period (6 month),a slight degree of enzyme 
induction has been reported. It was also reported that 
flupirtine delay the diuretic response to furosemide without 
affecting the magnitude of the response.There is no 
information related to  link between flupirtine and other 
hepatically metabolised drugs, also it is unclear that flupirtine 
represent pharmacokinetic or pharmacodynamic interaction 
between two drugs43-45. A single dose of flupirtine maleate, 
did not provoke significantly the diuretic action of frusemide 
when compared with indomethacin and placebo in normal 
human beings46. Flupirtine increased the hepatotoxic 
potential of paracetamol so that hepatic transaminases levels 
should be monitored when both the drugs are given 
concomitantly. Coadministration with carbamazepine is not 
advisable as carbamazepine induces hepatic enzymes. There 
is no information related to link between flupirtine and other 
hepatically metabolised drugs, also it is unclear that flupirtine 
represent pharmacokinetic or pharmacodynamic interaction 
between two drugs47.  
THERAPEUTIC USES  
Musculoskeletal Pain 
From a previous marketing observation of flupirtine 200-300 
mg/day for 1 week has shown improvement in response rate 
as assessed by visual analogue pain scale48. Flupirtine has 
been compared with placebo and diclofenac sodium (a 
standard analgesic), observation showed that the response 
rate of flupirtine in acute, sub-acute and chronic pain in 
patients was 94%, 89.4%, and 85.9%, respectively. 
Comparative studies with diclofenac 150 mg/day has also 
shown that flupirtine 300 mg/day significantly reduced 
postoperative pain equally. The pain reduction was significant 
after 60 min of oral administration of both the drugs. A 
random study revealed that flupirtine 300 mg/day was as 
effective as tramadol 150 mg/day in reducing sub- acute low 
back pain49-51. 
Headache 
Flupirtine showed significant response for chronic tension 
headache in those patients who had had insufficient response 
to conventional analgesics. In  comparative study of flupirtine 
100mg and placebo in chronic headache, flupirtine shown 
significant reduction in three time daily while  placebo shown 
reduction in pain intensity in 2 weeks. Flupirtine 100 mg has 
shown better efficacy in terms of pain relief in acute migraine 
effect restriction in working ability with less adverse effects 
when compared to paracetamol 1 gm orally 49,50. 
Neurogenic Pain 
A study shown that 380mg/day dose of flupirtine is more 
effective in comparison to aspirin 1800 mg/day in in reducing 
lumbar and cervical spinal root pain. The study also revealed 
that 25% of flupirtine-treated patients reported no pain and 
46% reported improvement, but in those who received 
aspirin only 35% reported an improvement. An early study of 
utilised a heat stimulation test to evaluate the ability of 
flupirtine, pentazocine and placebo, administered orally and 
intravenously, to increase the pain threshold in 6 healthy 
volunteers. Over a period of 60 minutes after doses of both 
analgesics, the pain threshold rose steadily, the level achieved 
being higher for flupirtine than for pentazocine. Feingold et al. 
(1982) also demonstrated an increase in pain threshold in 20 
healthy males after a single oral dose of flupirtine 50mg, using 
both an electrical stimulation test and a tourniquet technique 
to elicit ischaemic pain. The potency of flupirtine, measured 
on a visual analogue scale, was less than that of tramadol 
50mg but greater than that of dipyrone 500mg52-54. Thermic 
stimulation of the tooth pulp was used to measure pain 
threshold before and up to 60 minutes after a single oral dose 
of tlupirtine or placebo in 2 groups of 15 healthy volunteers. 
Flupirtine was statistically superior to placebo, producing a 
rise in pain threshold within 15 minutes which lasted up to 45 
minutes postdose55. Preclinical observations backed up the 
hypothetical neuroprotective effect of flupirtine derived from 
knowledge of its pharmacodynamic properties. In optic 
neuritis in the context of experimental autoimmune 
encephalomyelitis, flupirtine exerted neuroprotective effects 
both in the presence and absence of interferon (IFN)-β. 
Flupirtine and retigabine exerted neuroprotective actions in 
organotypic hippocampal cultures exposed to NMDA, oxygen, 
and glucose deprivation followed by reoxygenation or serum 
withdrawa56,57. In in-vitro studies on primary neurons, 
flupirtine significantly reduced the apoptotic effect displayed 
by A-beta 25 – 35, a fragment of the amyloid beta-protein, and 
prevented the toxic effect of PrP, the aetiological agent of CJD. 
Despite these results, no larger clinical trials with flupirtine 
for the treatment of Alzheimer’s disease have been performed 
so far 58. 
Cancer Pain 
According to the studies, flupirtine is more effective in 
reduction of cancer pain in comparison with tramadol and 
pentazocine. In addition, pentazocine showed a higher side 
effect incidence in central nervous system (CNS) although the 
adverse reaction profile was similar in both flupirtine and 
tramadol. In a study of cancer patients with metastatic 
involvement of myofascial or neural structures for whom 
opioid analgesics are contraindicated on account of their 
spasmogenic effects flupirtine offer a non sedating alternative 
to the benzodiazepines. Flupirtine has analgesic and muscle 
relaxant effects, thus expected to be particular benefit in 
relieving musculoskeletal and myofascial pain of the type 
frequently associated with non-inflammatory degenerative 
disease such as non-articular rheumatism, and sub acute and 
chronic spinal syndromes59-61. 
Fibromyalgia 
Flupirtine has shown more efficiency to reduced pain of 
fibromyalgia more than the available drugs. A Pharmaceutical 
company ADEONA was granted permission by US FDA to 
conduct randomized, double blind, placebo-controlled phase 
II clinical trial of flupirtine in Fibromyalgia syndrome60,62. 
Postoperative pain 
Flupirtine is more significant in analgesic effect with minimal 
side effects in pain during postoperative period when 
compared to standard drugs. Flupirtine showed 69% 
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reduction in pain score 6 h after administration when 
compared to placebo which had only 26% reduction in post-
episiotomy. Flupirtine also had greater efficacy in post 
episiotomy pain reduction when compared to suprofen and 
paracetamol62,63. 
Other effects 
An in vivo study revealed that flupirtine has an anti-diuretic 
property64. On the other hand, a single oral administration of 
flupirtine 200mg in healthy volunteers did not show any 
evidence of significant anti-diuretic action of (frusemide)48. 
An ocular toxicity study of flupirtine at 7 days oral 
administration of 200 to 400 mg/day in healthy volunteers 
showed no change in visual function. Studies showed that 
flupirtine produces only weak mydriasis and has no local 
anaesthetic activity in mice, but has a a weak local anaesthetic 
effect on the rabbit cornea64-66. In contrast, on topical 
application to the nasal mucosa of healthy volunteers, 
flupirtine (12 to 30mg) has a local anaesthetic effect, as 
reflected in a significant decrease in the amplitude of pain-
related chemo-somatosensory evoked potentials44. Veterinary 
pharmacology still has a reduced drug facilities compared to 
human pharmacology; however, human drugs are 
increasingly being investigated for veterinary use in order to 
address this shortfall. This has stimulated pharmaceutical 
companies to market drugs developed specifically for animal 
use as well as academia to perform experimental studies in 
veterinary species with human drugs. In this consequence, FL 
shown wide potential in veterinary pharmacology, it effects as 
a muscle relaxant is of added value for pain associated with 
increased muscle tension65-69. In addition, its mechanism of 
action promotes neuronal rest; it has proven useful in 
conditions involving neuronal hyperexcitability such as 
chronic pain (non-malignant and malignant), migraine and 
neurogenic pain70,71. 
CONCLUSION 
In the past decade significant researches has been done on the 
neuroprotective analgesic and effects of the drug but 
flupirtine should be explored as an adjunct analgesic also with 
opioids for the management of pain states involving central 
sensitization. It is an analgesic with many potential 
therapeutic benefits that has proved useful in the treatment of 
many diseases and diseases. Flupirtine can be used as an 
alternate analgesic because there is no seen of serious upper 
gastrointestinal side effects including bleeding, perforation, 
and obstruction associated in ulcer treatment, like other 
NSAIDs 
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